

1 Can routine antenatal data be used to
2 assess HIV antiretroviral therapy
3 coverage among pregnant women?
4 Evaluating the validity of different data
5 sources in the Western Cape, South
6 Africa

7
8 Nisha Jacob¹, Brian Rice², Alexa Heekes^{1,3}, Leigh F. Johnson¹, Samantha
9 Brinkmann³, Tendesayi Kufa^{4,5}, Andrew Boulle^{1,3}

10 ¹ School of Public Health, University of Cape Town, Cape Town, South Africa

11 ² University of Sheffield, Sheffield, United Kingdom

12 ³ Western Cape Government: Health and Wellness, South Africa

13 ⁴ Center for HIV and STI, National Institute for Communicable Diseases, Johannesburg,
14 South Africa

15 ⁵ School of Public Health, University of Witwatersrand, Johannesburg, South Africa

16

17

18

19

20

21

22

23

24

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 Abstract

26 Background

27 Accurate measurement of antenatal antiretroviral treatment (ART) coverage in pregnancy is
28 imperative in tracking progress towards elimination of vertical HIV transmission. In the
29 Western Cape, South Africa, public-sector individual-level routine data are consolidated from
30 multiple sources, enabling the description of temporal changes in population-wide antenatal
31 antiretroviral coverage. We evaluated the validity of different methods for measuring ART
32 coverage among pregnant women.

33 Methods

34 We compared self-reported ART data from a 2014 antenatal survey with laboratory assay data
35 from a sub-sample within the survey population. Thereafter, we conducted a retrospective
36 cohort analysis of all pregnancies consolidated in the Provincial Health Data Centre (PHDC)
37 from January 2011 to December 2020. Evidence of antenatal and HIV care from electronic
38 platforms were linked using a unique patient identifier. ART coverage estimates were
39 triangulated with available antenatal survey estimates, aggregated programmatic data from
40 registers recorded in the District Health Information System (DHIS) and Thembisa modelling
41 estimates.

42 Results

43 Self-reported ART in the 2014 sentinel antenatal survey (n=1434) had high sensitivity (83.5%),
44 specificity (94.5%) and agreement (k=0.8) with the gold standard of laboratory analysis of
45 ART. Based on linked routine data, ART coverage by the time of delivery in mothers of live
46 births increased from 67.4% in 2011 to 94.7% by 2019. This pattern of increasing antenatal
47 ART coverage was also seen in the DHIS data, and estimated by the Thembisa model, but
48 was less consistent in the antenatal survey data.

49 Conclusion

50 This study is the first in a high-burden HIV setting to compare sentinel ART surveillance data
51 with consolidated individuated administrative data. Although self-report in survey conditions
52 showed high validity, more recent data sources based on self-report and medical records may
53 be uncertain with increasing ART coverage over time. Linked individuated data may offer a
54 promising option for ART coverage estimation with greater granularity and efficiency.

55

56 Introduction

57 Accurate measurement of antenatal antiretroviral treatment (ART) coverage in pregnancy is
58 imperative in tracking progress towards the elimination of vertical transmission[1–3]. To
59 monitor progress towards elimination of vertical transmission, the Global Plan for the
60 elimination of mother-to-child transmission requires countries to report on three process
61 measures with the targets that 95% of pregnant women attend antenatal care, 95% are tested
62 for HIV and 95% of HIV positive pregnant women initiate ART prior to or during pregnancy[1].

63 Antenatal HIV sentinel surveillance is one approach to measuring these process indicators,
64 and is a long-standing tool used in South Africa[4–7]. Since 1990, antenatal HIV sentinel
65 surveys have taken place annually or biennially in all provinces of South Africa. Until 2015,
66 the Western Cape province of South Africa extended the national survey to a larger
67 proportionally weighted sample to generate sub-district level estimates. The World Health
68 Organization (WHO) has recommended sentinel surveillance be replaced by routine
69 programmatic data, a shift that is reliant on accurate and complete routine data[7,8]. While the
70 focus of sentinel antenatal surveys is HIV seroprevalence, the widespread roll-out of ART
71 necessitates the monitoring of ART coverage in conjunction with prevalence to accurately
72 measure progress in managing HIV and preventing transmission[9].

73 In 2013, the Western Cape province of South Africa adopted a policy of lifelong ART for all
74 pregnant women living with HIV (WLWH) (Option B+)[10,11]. Subsequently, the Western

75 Cape Provincial Department of Health (WCDOH) added an additional question on ART use to
76 the 2014 provincial antenatal survey, which was also incorporated in national surveys [12–14].
77 This question measured current ART use in the 3 days prior to survey participation[12]. The
78 validity of self-reported ART use as a method to evaluate ART coverage using existing sentinel
79 surveillance methods requires formal evaluation. An alternative method for measuring ART
80 use is using routine data. The WCDOH makes use of two routine health information platforms.
81 Firstly, aggregated data from facility-based registers are captured in the District Health
82 Information System (DHIS). Secondly, individuated electronic patient data are consolidated
83 by the Provincial Health Data Centre (PHDC). These include administrative, pharmacy and
84 laboratory data linked via a unique patient folder number, in the absence of electronic medical
85 records. ART coverage can therefore be estimated using pharmacy dispensing data of triple-
86 regimen ART or entries in HIV treatment registers.

87 We evaluated the validity of different methods for measurement of ART coverage by assessing
88 self-reported ART use in sentinel antenatal surveys and comparing sentinel survey estimates
89 with routine programmatic data estimates over a 10-year period.

90 **Methods**

91 This study was conducted in the Western Cape province of South Africa. The province is
92 comprised of six districts: Cape Metro, Overberg, Garden Route, Central Karoo, West Coast
93 and Cape Winelands. The study was comprised of two parts: validation of 2014 self-reported
94 ART data with laboratory data, and the comparison of cross-sectional sentinel survey ART
95 coverage estimates as well as modelling estimates with routine data from 2011 to 2020. The
96 datasets used are described below.

97 **Antenatal survey data**

98 Antenatal ART coverage estimates for the Western Cape Province for 2014 and 2015 were
99 obtained from the Western Cape provincial sentinel antenatal survey. In 2016, the provincial
100 survey was discontinued and annual national surveys were replaced by biennial surveys.

101 Antenatal ART coverage estimates for the Western Cape province for 2017 and 2019 were
102 obtained from the South African National Department of Health as reported in the national
103 sentinel antenatal survey reports.

104 Estimates were derived from data that included all pregnant women attending their first
105 antenatal visit in a public health facility during a 6-week period of a survey in years 2014 and
106 2015. In years 2017 and 2019, the national survey data included pregnant women attending
107 first antenatal visits or follow-up antenatal visits in a public health facility during a 6-week
108 period (in this current analysis, only data collected at first antenatal visit are included). The
109 survey question for current ART use in 2014, 2015 and 2017 surveys was: “Have you taken
110 ARVs in the last 3 days?”. This question measured ART use at enrolment as a proxy for ART
111 use prior to the pregnancy or by the time of conception, excluding any prior treatment
112 interruption. This question was discontinued in 2019. In 2017 and 2019, participants were
113 asked if they had ever taken ARVs and if so when, therefore measuring any ART use (prior or
114 current). From 2019, the health care worker asking the question was further expected to verify
115 the response with information in the participant’s medical records if available.

116 **Laboratory validation sub-sample**

117 As part of a WCDOH analysis, a third of the HIV positive specimens from the 2014 provincial
118 antenatal survey were sampled, stratified by district, obtaining a sub-sample of 450
119 specimens. These were tested by the University of Cape Town (UCT) Department of
120 Pharmacology for lopinavir, efavirenz and nevirapine, using a cut-off of 50ng/ml. At least one
121 of these drugs were included in all ART regimens in use in South Africa in 2014. These data
122 were used to validate the additional survey question on current ART use introduced in the
123 2014 provincial antenatal survey.

124 **Provincial Health Data Centre (Routine individual-level HIV program data)**

125 A retrospective cohort of pregnancies was enumerated from the PHDC on 26 May 2022, which
126 included anonymised linked data of all pregnant women attending public health facilities in the

127 Western Cape between 2011 to 2020. Pregnancies were allocated a quantitative confidence
128 score to measure the degree of confidence in the recorded information/data points, indicating
129 a true pregnancy. Pregnancies scoring 0.7 or higher out of a maximum of 1 were included as
130 they have at least 1 high confidence data point such as a rhesus antibody test (conducted
131 routinely at first antenatal visit), pregnancy test, International Classification of Diseases (ICD)
132 Tenth Revision code indicating pregnancy, antenatal visit or maternal discharge summary.
133 The geographic location of the facility of first pregnancy-related attendance was used to
134 determine district of pregnancy. Pregnancy outcome date and available information on
135 gestational age were used to estimate pregnancy period, with the date of the first evidence of
136 pregnancy used to stratify pregnancies by year. Within this cohort, administrative, laboratory
137 and pharmacy evidence of HIV diagnosis before or during the estimated pregnancy period
138 was used to determine antenatal HIV status. Antenatal ART coverage was based on the
139 proportion of women known to be living with HIV during the antenatal period with evidence of
140 ART initiation before or during pregnancy. Women who interrupted treatment would be
141 included as having started ART by enrolment.

142 **District Health Information System (Routine aggregated HIV program data)**

143 Aggregated program data of women recorded as attending public antenatal facilities in the
144 Western Cape for the first time in 2011 to 2020 were included in the DHIS dataset. For this
145 analysis, the element “Known HIV positive client on ART at first visit” was used to determine
146 ART coverage at first antenatal visit among all those known with HIV before pregnancy and
147 diagnosed with HIV at first antenatal visit. This data element is intended to measure ART use
148 at conception and excludes women who had interrupted treatment at the time of the first
149 antenatal visit.

150 **Thembisa Model**

151 Thembisa is an integrated demographic and HIV model, developed for South Africa. The
152 model is applied at both national and provincial levels; the estimates used in this study are

153 from version 4.6 of the Western Cape model[15]. The provincial model is calibrated to a
154 number of HIV data sources: age-specific HIV prevalence data from antenatal clinic surveys
155 and household surveys, recorded numbers of deaths by age and sex, total numbers of ART
156 patients and age/sex distributions of ART patients, and antiretroviral metabolite data.
157 Assumptions about fertility rates in HIV-positive women and the effect of ART on fertility are
158 informed by Western Cape PHDC data[16]. The model makes assumptions about rates of
159 ART interruption and re-initiation, which make it possible to estimate both current ART
160 coverage and proportions of WLWH ever initiated on ART at the time of conception.

161 Analysis

162 Data were analysed using Stata 17 (Stata Corporation, College Station, Texas, USA).
163 Descriptive characteristics of the laboratory validation sub-sample were tabulated. Given the
164 higher validity of laboratory-based ART testing[17], this dataset functioned as the gold
165 standard for comparison with the newly introduced survey question in 2014[9]. Discordance
166 between self-report and laboratory ART was calculated. Demographic risk factors for
167 discordance were analysed using logistic regression. Sensitivity, specificity, positive predictive
168 value and negative predictive value were calculated to validate the survey question on ART
169 use. Agreement between self-report and lab ART detection was quantified using the kappa
170 statistic.

171 Given the 10-year duration of the PHDC cohort (2011 – 2020) and the notable changes in
172 ART guidelines and data availability over this time period, descriptive characteristics of the
173 cohort were tabulated across all years and for the 2019 cohort specifically, as the most recent
174 year pre-COVID19, to reflect the most recent characteristics.

175 ART-specific survey data and time trends from 2014 to 2019 were compared with PHDC,
176 DHIS and Thembisa 4.6 estimates. The 2014 and 2015 provincial antenatal survey measured
177 current ART use (excluding treatment interruption). The 2017 and 2019 national antenatal
178 surveys measured any ART use before pregnancy (which may include treatment interruption).

179 ART coverage estimates from the surveys were compared with PHDC estimates for women
180 initiating ART before pregnancy among those with prenatal or antenatal evidence of HIV
181 diagnosis (includes treatment interruption). The survey data were similarly compared with
182 DHIS data which were limited to first visit ART coverage (excluding treatment interruption).
183 The survey estimates, PHDC ART coverage estimates before pregnancy and DHIS estimates
184 were further compared with ART at conception estimates from the Thembisa mathematical
185 model estimates for the Western Cape, with and without treatment interruption [15].

186 PHDC estimates for women initiating ART before or during pregnancy among those with
187 prenatal or antenatal evidence of HIV diagnosis (both with live births or any pregnancy
188 outcome) were further compared with Thembisa estimates of ART at delivery among those
189 with live births. A sensitivity analysis including moderate-low confidence pregnancies was
190 conducted to determine the contribution of these pregnancies to ART coverage. The PHDC
191 data were analysed further for estimates of ART coverage by district and age-group. These
192 analyses were limited to a 5-year period (2015 – 2020) when the test and treat ART policy
193 was fully implemented and individualised electronic data systems were better established.

194 Ethical considerations

195 The study was approved by the University of Cape Town Human Research Ethics Committee
196 (HREC 083/2021) and the Western Cape Provincial Health Research Committee. All antenatal
197 HIV survey data, DHIS and Thembisa data were provided in aggregated form. Data from the
198 PHDC were de-identified before study release according to the Western Cape Department of
199 Health Data Access Policy Guidelines.

200 Results

201 From 1 January 2011 to 31 December 2020, 977 800 and 989 568 pregnancies were recorded
202 by the PHDC and DHIS, respectively, with the PHDC enumerating more pregnancies than
203 DHIS from 2015 onwards. Sample sizes for the provincial surveys in 2014 and 2015 were

204 7470 and 7517, respectively. Following the discontinuation of provincial surveys, the Western
 205 Cape sample size of the national surveys in 2017 and 2019 were 3571 and 3943, respectively.
 206 The descriptive characteristics of the laboratory sub-sample were comparable to the 2014 HIV
 207 positive survey population (Table 1). Within the sub-sample, 13 participants (2.9%) did not
 208 disclose ART status.

209 **Table 1: Characteristics of HIV-positive women in the laboratory validation sub-**
 210 **sample compared to antenatal survey, 2014**

		Lab sub-sample (N=450)		2014 Antenatal Survey (N=1434)	
Variable		Median, Percentage	95% Confidence interval	Median, Percentage	95% Confidence interval
District	Cape Winelands	12.0 %	9.3- 15.4	11.9 %	10.3 -13.6
	Central Karoo	0.5 %	0.1 – 1.8	0.5 %	0.2 – 1.0
	Cape Metro	61.9 %	57.3 – 66.3	62.1 %	59.5 – 64.5
	Garden Route	14.0 %	11.1 – 17.6	14.0 %	12.3 – 15.9
	Overberg	4.5 %	2.9 – 6.8	4.4 %	3.5 – 5.6
	West Coast	7.1 %	5.1 -9.9	7.2 %	6.0 – 8.6
Age in years (median; IQR)		28	IQR 24 - 33	29	IQR 24 -33
Age category	10-14	0.2 %	0.03 – 1.6	0.1 %	0.01 – 0.5
	15-19	5.5 %	3.7 – 8.0	4.3 %	3.3 – 5.5
	20-24	20.7 %	17.2 -24.8	22.8 %	20.7 – 25.1
	25–29	29.8 %	25.7 – 34.3	30.1 %	27.7 – 32.5
	30-34	27.6 %	23.6 – 31.9	27.7 %	25.4 – 30.0
	35-39	13.7 %	10.8 – 17.2	12.7 %	11.1 – 14.6
	40-44	2.3 %	1.2 – 4.2	2.2 %	1.6 – 3.1
	45-49	0.2 %	0.03 – 1.6	0.1 %	0.04 – 0.6
Age of partner in years (median; IQR)		32	IQR 28 -32	32	IQR 28 - 37
Gravidity	1	22.4 %	18.8 – 26.5	19.2 %	17.6 – 21.7
	2	37.4 %	33.1 – 42.0	35.5 %	33.0 – 37.9
	3	25.1 %	21.3 – 29.4	28.7 %	26.4 – 31.0
	4	10.3 %	7.8 – 13.5	12.0 %	10.3 – 13.7
	5	3.6 %	2.2 – 5.8	3.2 %	2.3 – 4.1
	6	0.9 %	0.3 -2.3	1.0 %	0.6 -1.7
	>6	0.2 %	0.03 – 1.6	0.4 %	0.1 – 0.8
Population group	Black African	85.7 %	82.1 – 88.6	85.8 %	83.9 – 87.5
	Coloured*	14.3 %	11.4 – 17.9	13.9 %	12.2 – 15.8
	None	3.0 %	1.7 – 5.1	2.2 %	1.6 – 3.2

Level of education	Finished primary	52.5 %	47.8 – 57.2	52.1 %	49.5 – 54.8
	Finished secondary	42.0 %	37.5 – 46.7	43.2 %	40.6 – 45.8
	Finished tertiary	2.5 %	1.4 – 5.1	2.5 %	1.8 – 3.4
Marital status	Single	75.8 %	71.6 – 79.6	76.1 %	73.8 – 78.3
	Married	21.9 %	18.3 – 26.0	22.3 %	20.2 – 24.6
	Widow	1.4 %	0.6 – 3.0	0.7 %	0.3 – 1.2
	Divorced	0.9 %	0.3 -2.4	0.9 %	0.5 – 1.5
Awareness of HIV status	Yes	91.0 %	88.0 – 93.4	90.3 %	88.6 – 91.7
	No	9.0 %	6.6 – 12.0	9.7 %	8.3 – 11.4
Self-reported ART use**		35.0 %	30.7 – 39.6	35.5 %	33.0 – 38.1
ART detected on lab analysis		37.2 %	32.8 – 41.8		
	Lopinavir (LPV)	3.3 %	2.0 – 5.5		
	Efavirenz (EFV)	31.2 %	27.1 – 35.6		
	Nevirapine (NVP)	2.7 %	1.5 -4.7		
Overall discordance		9.6 %	7.2 -12.8		
	Discordance – ART self-reported but not detected	3.4 %	2.1 – 5.6		
	Discordance – ART detected but not self-reported	6.2 %	4.3 – 8.9		

211

212 **This term is applied by the national survey for purposes of service delivery redress*

213 ***Sensitivity 83.5% (95% CI 77.0 – 88.9), specificity 94.5% (95% CI 91.1 – 96.9), kappa 0.8 (p<0.001), NPV 90.5% (95% CI*
214 *86.5 – 93.6), PPV 90.1% (95% CI 84.2 – 94.4)*

215 No risk factors for discordance between the laboratory sub-sample and 2014 survey
216 population were noted on bivariable and multivariable analyses. Self-reported ART use (35%)
217 was similar to ART detected on lab analysis (37.2%), with 2.2% absolute difference. Self-
218 reported ART was further compared to laboratory markers showing a sensitivity of 83.5% (95%
219 CI 77.0 – 88.9) and a specificity of 94.5% (95% CI 91.1 – 96.9), positive predictive value of
220 90.1% (95% CI 84.2 – 94.4) and negative predictive value of 90.5% (95% CI 86.5 – 93.6).

221 Agreement between self-report and laboratory markers was also high at 90.4% (kappa statistic
222 0.8, $p < 0.001$).

223

224 Descriptive characteristics of the PHDC cohort are summarised in Table 2. The majority of
225 women (69.8%) having no electronic record of HIV status, suggests either HIV negative (most
226 commonly given high antenatal HIV testing coverage) or unknown status. Of those with
227 electronic records of positive HIV status, 7.7% had no record of ART (Table 2). Of all pregnant
228 women with HIV in the 10-year cohort, 72.6% (95% CI 72.4 – 72.8) had records of ART
229 initiation before or during pregnancy and 87.2% (95% CI 86.8 – 87.6) in 2019.

230 **Table 2: Descriptive and HIV-specific characteristics of PHDC Cohort (2011 – 2020)**
231 **compared to PHDC Cohort 2019**

232

	PHDC Cohort 2011 – 2020 (n=977800) Percentage	95% CI	PHDC Cohort 2019[§] (n= 123907) Percentage	95% CI
Prior electronic evidence of pregnancy*				
1	60.3%	60.2 – 60.4	52.4%	52.1 – 52.6
2	27.2%	27.1 – 27.3	29.7%	29.5 – 30.0
3	9.2%	9.2 – 9.3	12.4%	12.2 – 12.6
4	2.5%	2.48 – 2.54	4.0%	3.9 – 4.1
5 or more	0.8%	0.8 – 0.9	1.5%	1.4 – 1.6
Age (median; IQR)	27.4	22.5 – 31.8	27.2	22.8 – 32.3
Age Category				
<15	0.5%	0.4 – 0.5	0.5%	0.4 – 0.5
15 -19	12.0%	12.0 – 12.1	11.1%	10.9 – 11.3
20 - 24	26.6%	26.5 – 26.7	25.7%	25.5 – 26.0
25 - 29	27.4%	27.3 – 27.5	27.3%	27.1 – 27.6
30 - 34	20.1%	20.1 – 20.2	20.8%	20.6 – 21.0
35 - 39	10.4%	10.3 – 10.4	11.5%	11.3 – 11.7
>39	3.0%	2.97 – 3.03	3.1%	3.0 – 3.2
District**				
Cape Winelands	13.4%	13.3 – 13.5	13.1%	12.9 – 13.2
Central Karoo	0.8%	0.7 – 0.8	1.2%	1.1 – 1.3

Cape Metro	70.2%	70.1 – 70.3	65.7%	65.4 – 65.9
Garden Route	8.3%	8.3 – 8.4	9.2%	9.0 – 9.4
Overberg	3.0%	2.9 – 3.0	4.3%	4.2 – 4.4
West Coast	3.7%	3.7 – 3.8	5.5%	5.4 – 5.6
No district recorded	0.6%	0.61 – 0.64	1.1%	1.0 – 1.1
Pregnancy Outcomes				
Delivered	83.4%	83.3 – 83.5	81.1%	80.1 – 81.3
Ectopic pregnancy	1.4%	1.4 – 1.5	1.7%	1.7 – 1.8
Termination	5.4%	5.3 – 5.4	7.2%	7.1 – 7.4
Stillbirth	1.5%	1.4 – 1.5	1.3%	1.2 – 1.4
Miscarriage	3.4%	3.4 – 3.5	4.9%	4.8 – 5.0
Mother died prior to delivery	0.02%	0.01 – 0.02	0.02%	0.01 – 0.03
Outcome unknown	4.9%	4.86 – 4.94	3.8%	3.7 – 3.9
Evidence of HIV status				
HIV status unknown†	69.8%	69.8 – 69.9	71.6%	71.6 – 72.1
HIV status known	30.2%	30.1 – 30.3	27.9%	27.9 – 28.4
HIV evidence timing				
HIV positive before or during pregnancy	16.7%	16.7 – 16.8	18.5%	18.3 – 18.7
HIV positive postnatally	4.0%	4.00 – 4.03	1.4%	1.3 – 1.5
HIV negative	9.5%	9.4 – 9.5	8.3%	8.1 – 8.4
HIV unknown	69.8%	69.7 – 69.9	71.8%	71.6 – 72.1
ART (n=202575)			(n=24644)	
HIV Positive but no evidence of ART	7.7%	7.6 – 7.8	5.9%	5.6 – 6.2
Antenatal ART (before or during pregnancy)	72.6%	72.4 – 72.8	87.2%	86.8 – 87.6
Postnatal ART	19.7%	19.6 – 19.9	6.9%	6.6 – 7.2
Antenatal ART (n=163649)‡			(n=22910)	
ART started before pregnancy	54.7%	54.4 – 54.9	69.5%	68.9 – 70.1
ART started during pregnancy	35.2%	35.0 – 35.4	24.3%	23.7 – 24.9
No antenatal ART	10.1%	10.0 – 10.3	6.2%	5.9 – 6.5

233

234 *§2019 reflects the most recent characteristics pre COVID-19*

235 **Gravidity estimates in the PHDC are not reliable since historic data are incomplete. Prior electronic evidence is used as a*
236 *proxy to provide a full description of the cohort.*

237 ***Unweighted*

238 *†HIV diagnosis is based on point-of-care tests that are not recorded electronically. Unknown HIV status therefore includes*
239 *those who tested negative on point-of-care tests and therefore have no subsequent electronic evidence of HIV*

240 *‡Excludes women who only tested HIV positive postnatally*

241

242 Among those living with HIV, survey, DHIS, PHDC and Thembisa estimates show that ART
243 coverage before pregnancy increased over time, however a slight decrease is noted in the
244 survey estimate in 2019 (Table 3 and Figure 1). The 2014 laboratory and PHDC estimates of
245 ART coverage were almost the same (37.2% v 37.4%, respectively). The 2015 survey
246 estimate of 44.2% was similar to the PHDC estimate of 42.8%. The 2017 survey estimate of
247 62.3% was higher than PHDC data (58.4%), but lower in 2019 (61.2%) compared to PHDC
248 (69.5%), when comparing ART coverage before pregnancy. DHIS estimates were notably
249 higher than Thembisa estimates, excluding treatment interruption, and more aligned to PHDC
250 estimates which included treatment interruption. Thembisa estimates of those ever on ART
251 prior to conception (including treatment interruption), were higher than PHDC until 2016 and
252 thereafter reasonably close to PHDC estimates. From 2015 to 2020, Thembisa estimates of
253 ART at delivery were higher than PHDC estimates of ART at delivery, however the difference
254 between estimates is lower when restricting PHDC estimates to live births only. A sensitivity
255 analysis to assess the contribution of moderate-low confidence pregnancies to ART coverage
256 did not materially impact the PHDC estimates and associated comparisons.

257 **Table 3: Western Cape Antenatal ART Coverage (%) amongst women living with HIV by dataset (2011 – 2020)**

	Before pregnancy						At delivery		
	Antenatal Survey		DHIS	Thembisa 4.6	PHDC	Thembisa 4.6	PHDC	PHDC	Thembisa 4.6
Year	Antenatal Survey (on ART among WLWH)	Lab validation	Proportion on ART among those with HIV at antenatal first visit (excluding treatment interruption)	Antenatal ART coverage prior to conception (excluding treatment interruption)	Proportion on ART before pregnancy among those known with HIV (including treatment interruption)	Antenatal ART coverage prior to conception (including treatment interruption)	Antenatal ART coverage at delivery (all pregnancy outcomes)	Antenatal ART coverage at delivery (live births only)	Antenatal ART coverage at delivery (live births only)
2011				32.4	27.0	34.8	67.1	67.4	51.7
2012				36.0	33.7	39.2	72.8	73.9	62.3
2013				39.7	35.4	43.5	83.7	85.3	77.0
2014	35.5 (33.0 - 38.0)*	37.2 (32.7 - 41.7)*		43.4	37.4	47.6	88.9	90.6	88.6
2015	44.2 (41.6 - 46.8)*		43.9	47.3	42.8	52.0	90.6	92.4	93.8
2016			51.4	51.0	51.6	56.5	91.4	92.9	95.3
2017	61.5 (57.7 - 65.1)* 62.3 (58.5 - 66.0)**		62.0	54.1	58.4	60.5	92.4	93.9	96.1
2018			62.9	57.1	63.6	64.1	92.6	94.0	96.4
2019	61.2 (57.2 - 65.1)**		68.3	59.7	69.5	67.3	93.8	94.7	96.6
2020			70.1	61.3	72.6	69.5	93.5	94.1	96.7

258

259 *Current ART use (excludes treatment interruption)

260 ** Includes treatment interruption. Stratified to first visit only. ART before pregnancy amongst first and follow-up attendees is 58.4 for 2017 and 58.2 for 2019.

261 **Figure 1: ART coverage before and during pregnancy by dataset (2011 – 2020)**

262 Figure 2 presents Western Cape antenatal ART coverage among those with HIV over a 10-
263 year period according to PHDC data. ART coverage prior to pregnancy amongst women living
264 with HIV increased over time from 42.8% (95% CI 42.0 - 43.5) in 2015 to 72.6% (95% CI 72.0
265 - 73.1) in 2020. Higher coverage was observed in older age groups, with coverage as high as
266 81.1% in the 35-39 age group in 2020 (Figure 1). An increasing proportion of women are
267 shown to be on ART before pregnancy and from 2015 onwards ART coverage exceeds 90%
268 before or during pregnancy. ART coverage during the antenatal period (ART commenced
269 before or during pregnancy) was high amongst pregnant WLWH in all districts, except Central
270 Karoo, and across all years. Over time, there was variability of coverage estimates in Central
271 Karoo, Overberg and West Coast, with Cape Metro having the most consistent increase in
272 coverage.

273 **Figure 2: Temporal trends in antenatal ART coverage in the Western Cape by timing,**
274 **district and age (PHDC)**

275 **Discussion**

276 Our study is the first to assess and compare different methods of antenatal ART coverage
277 ascertainment in the Western Cape province. All datasets documented the increasing ART
278 coverage in pregnant women over time. The challenges in dataset comparisons where
279 numerators and denominators are disparate were highlighted.

280 The self-reported survey-based antenatal ART question was confirmed as a valid measure of
281 ART use by comparison to the gold standard of laboratory detection, with good overall
282 concordance. Discordance was higher amongst those self-reporting no ART use but having
283 positive laboratory detection of ART than vice versa. This may represent misunderstanding of
284 the question, false positive laboratory results or reluctance in disclosing ART use due to stigma
285 or other reasons. Interestingly, 15 participants who self-reported ART use had no laboratory
286 evidence of ART. In addition to question misinterpretation or false negative laboratory results,
287 this may also suggest poor recent medication adherence. Discordance proportions and

288 agreement between self-report and laboratory detection were in keeping with a similar study
289 conducted in the Kwazulu-Natal province, however non-disclosure of ART status (2.9%) was
290 notably lower in our cohort compared to this study[9]. Several other studies in sub-Saharan
291 Africa comparing self-report and biomarkers of current or previous ART use showed higher
292 proportions of ART non-disclosure, however these studies had smaller sample sizes and the
293 study population was not restricted to pregnant women presenting for antenatal care[18–21].
294 While the study by Huerga et. al. in Kwazulu Natal found younger individuals were at higher
295 risk of discordance, our study found no demographic risk factors for discordance[9]. The ART
296 question had high agreement beyond chance, and high specificity, sensitivity and positive and
297 negative predictive values, suggesting good performance of this question as a measure of
298 ART use. Other studies have shown a similarly high specificity and positive predictive value,
299 however sensitivity and negative predictive value are notably lower[22–24]. Reasons for better
300 performance of self-reported ART in our study may include lower social desirability bias due
301 to lower perceived stigma of ART use amongst those actively seeking antenatal care in a
302 clinical setting. Furthermore, since the ART question was asked by clinicians during routine
303 clinical care, more explanation of the question may have been given compared to other study
304 settings. Our findings arguably support the continued use of the question in survey settings
305 and the utility of survey ART estimates for further validation with routine data. However, we
306 note that the question on current ART use was discontinued after 2017 and replaced with a
307 question “has the participant ever taken ARV’s,” thereby including those not on ART at the
308 time due to prior treatment interruption. Additionally, from 2019, survey questions were
309 complemented with information from medical records if available. Further validation of survey
310 data is therefore recommended.

311 From 2015 onwards, the PHDC enumerated more pregnancies than DHIS, suggesting good
312 completeness of these data. Higher numbers in the PHDC may be due to inclusion of non-
313 viable pregnancies and terminations of pregnancy, which may not be captured in DHIS
314 amongst antenatal service attendees. Lower enumeration prior to 2015 is likely due to less

315 well-established electronic systems in earlier years. Within the PHDC cohort, 69.8% had no
316 information of HIV status. This is likely representative of the HIV negative antenatal population
317 whose HIV status is determined solely by point-of-care rapid HIV testing, the results of which
318 are not captured electronically on routine information systems [25]. Those with evidence of
319 HIV negative status had laboratory confirmation via HIV ELISA test results which are captured
320 electronically on routine systems. Those testing positive for HIV on point-of-care testing may
321 have further validation of test results by laboratory HIV ELISA testing as well as other
322 laboratory, pharmacy and administrative evidences of HIV, thus providing a complete dataset
323 of HIV positive antenatal patients in the public sector of the Western Cape province [25].

324 Estimates of ART coverage in the HIV positive antenatal population were similar across the
325 survey and PHDC datasets for 2014 and 2015, although higher estimates were expected in
326 2015 due to inclusion of treatment interruption in the PHDC dataset. The 2017 and 2019
327 antenatal surveys report ART use prior to pregnancy among women presenting for their first
328 antenatal visit, and therefore may include those who interrupted treatment [13,14]. When
329 compared to PHDC estimates of ART before pregnancy, PHDC estimates were lower than
330 survey estimates in 2017, but notably higher in 2019. The differences between survey
331 estimates and PHDC may reflect sampling bias in the survey population as well as interviewer-
332 related differences in asking the survey question on ART use prior to pregnancy, participant-
333 related interpretation of the question as well as availability of relevant medical records in 2019
334 survey participants. Whether the estimates include or exclude treatment interruption may be
335 dependent on how the survey question was interpreted by both interviewer and participant.

336 Thembisa estimates of ART at delivery were higher than PHDC estimates, however the
337 difference was slightly less when restricting PHDC estimates to live births only. This may
338 indicate that ART initiation is prioritised where transmission to an infant is possible, and less
339 urgent in non-viable pregnancies such as ectopic pregnancies. Additionally, pregnancies
340 where the outcome is unknown may represent those who are lost to the health care system
341 for reasons such as migration to a different province and therefore not recorded on ART within

342 the PHDC. The high ART coverage estimates reflected in the PHDC dataset is reassuring and
343 in keeping with recent literature[26]. These findings support the importance of antenatal first
344 visits for early engagement in HIV care and effective prevention of vertical transmission of
345 HIV. Any antenatal engagement with health services for WLWH, regardless of pregnancy
346 intention or outcome, should be considered an opportunity for ART initiation in keeping with
347 test and treat guidelines. Systemic factors associated with delayed ART initiation requires
348 urgent research in order to optimise prevention of vertical transmission of HIV.

349 DHIS estimates of ART coverage among WLWH at first antenatal visit are notably higher than
350 survey estimates and Thembisa estimates and more aligned to PHDC estimates, despite
351 differences in treatment interruption ascertainment. The reasons for these disparities may be
352 multifactorial and difficult to identify. It should be noted that Thembisa estimates include both
353 the private and public sector. When including treatment interruption, Thembisa estimates are
354 notably higher than PHDC estimates until 2016. PHDC estimates may be higher in recent
355 years and increasing over time due to greater ascertainment of patients using the public sector
356 for HIV services. Overall, PHDC estimates appear to track Thembisa estimates closely in
357 recent years, supporting the use of these routine individuated data for surveillance purposes
358 in this setting. DHIS estimates include those currently on ART (excluding those interrupting
359 ART) and trends may further represent changes in capturing of routine information on service-
360 based registers or other contextual factors. While DHIS indicators are clearly defined, the
361 exact question asked to ascertain current ART use at first antenatal visit may differ from
362 clinician to clinician, resulting in variable patient interpretation and responses. Where data is
363 not collected for research purposes it is difficult to determine how a question is asked. Data
364 sources based on responses therefore may be uncertain, particularly with increasing ART
365 coverage over time.

366 Population-wide datasets from the PHDC allow better discernment of current ART versus ever
367 on ART and more detailed analysis such as district-level and age disaggregated temporal
368 trends, which the antenatal survey is underpowered to generate, while the DHIS is limited to

369 specific indicators. Age-group trends over time show an expected higher ART coverage prior
370 to pregnancy in older age groups who have likely had more opportunities for HIV diagnosis
371 and care than younger age groups (in whom HIV is likely to have been more recently
372 acquired). District-level trends are in keeping with provincial trends, showing a high ART
373 coverage during the antenatal period, with most districts above 90%. The lower and less
374 precise coverage estimates in Central Karoo are reflective of the smaller population and lower
375 HIV prevalence in this sparsely populated rural district. Other demographic characteristics
376 associated with ART coverage could not be evaluated as these are not routinely captured in
377 health information systems.

378 Limitations

379 Routine data are subject to various caveats impacting both quality and completeness. Given
380 the wide range of information systems used and the diverse staff members involved in data
381 capturing, these data are subject to varying administrative and capturing errors. Completeness
382 of data cannot be accurately quantified as demonstrated in the limited PHDC data available
383 prior to 2015. Contextual factors at different facilities may further impact the quality of data -
384 this includes changes in capturing approaches, staff training, staff turnover, and COVID-19
385 pandemic impacts. Ascertainment of both pregnancy and ART use is dependent on how
386 electronic systems are used in different facilities. However, the PHDC approach to using
387 multiple data sources to enumerate pregnancy and HIV ascertainment, may mitigate against
388 gaps in single data sources such as DHIS. ART coverage ascertained from routine data is
389 inferred through dispensing of ART from pharmacy. This does not necessarily translate to
390 administration and adherence to ART.

391 This study highlights the challenges in comparing datasets with differing numerators and
392 denominators, particularly with respect to treatment interruption. Routine data are limited to
393 variables captured routinely. Since information specific to the first antenatal visit is not routinely
394 captured in all public health facilities, it was not possible to distinguish between first and follow-
395 up antenatal visits in the PHDC dataset. While first visit can be ascertained in DHIS,

396 aggregated data are susceptible to double counting if the patient attends multiple antenatal
397 clinics.

398 Detailed demographic and treatment characteristics are not captured, precluding a deeper
399 understanding of epidemiological trends. DHIS consists of data elements for both national and
400 provincial reporting purposes, some of which measure the same variable but are captured in
401 different registers and by different staff members. As such, different data elements may be
402 used for both numerator and denominator in order to calculate ART coverage. ART estimates
403 may therefore vary depending on the data elements selected.

404 Since the national antenatal survey is underpowered for detailed estimates, routine data
405 cannot be adequately validated at district, sub-district and age-group levels. Furthermore, the
406 findings on self-reported ART use in surveys reflect findings in the last decade. We
407 recommend repeating the validation to confirm if this concordance has persisted.

408 Lastly, it should be noted that while Thembisa estimates were used for comparison with
409 antenatal survey and PHDC estimates, the Thembisa model is partially dependent on
410 estimates from the antenatal survey for model calibration and assumptions on fertility are
411 derived from the PHDC.

412 Conclusion

413 Our study demonstrates the validity and utility of antenatal ART coverage using routine
414 individuated data. While laboratory detection is the most accurate measure of ART use, this
415 is neither affordable nor practical at a population level. Routine individuated data provide an
416 efficient and less costly method of estimation compared to surveys and more accuracy and
417 granularity than aggregate data. Trends in the Western Cape province are reassuring in that
418 the large majority of HIV positive women are initiated on ART before or during pregnancy. This
419 is supportive of the province soon meeting the third target of the Global Plan for elimination of
420 mother-to-child transmission of 95% of HIV positive women initiating ART prior to or during
421 pregnancy. Reasons for non-initiation during pregnancy require further investigation as this

422 has serious implications for prevention of vertical transmission and child morbidity and
423 mortality. Strengthening of routine information systems, including improved digitisation of
424 point-of-care HIV testing and ascertainment of treatment interruption, in addition to being
425 invaluable tools to directly support patient care, may allow more accurate epidemiological
426 trend analysis for timely action and improved quality of HIV care.

427 Acknowledgements

428 The authors gratefully acknowledge the contributions of various collaborators, including
429 Selamawit Woldesenbet, Emma Kalk, Florence Phelenyane, Adrian Puren, Kathryn Stinson,
430 University of Cape Town Department of Pharmacology, the Western Cape Department of
431 Health, the National Institute of Communicable Diseases, the South African National
432 Department of Health and the Measurement and Surveillance of HIV Epidemics (MeSH)
433 consortium.

434 Funding

435 We gratefully acknowledge funding from the Bill and Melinda Gates Foundation
436 (OPP1191327).

437 References

- 438 1. World Health Organization. Global guidelines on criteria and processes for validation:
439 elimination of mother-to-child transmission of HIV and Syphilis monitoring. *Int J*
440 *Gynecol Obstet.* 2014;143:155–6.
- 441 2. UNAIDS/World Health Organisation Working Group on Global HIV/AIDS and STI
442 surveillance. Guidelines for assessing the utility of data from prevention of mother-to-
443 child transmission (PMTCT) programmes for HIV sentinel surveillance among
444 pregnant women. 2013; Available from:
445 https://www.ncbi.nlm.nih.gov/books/NBK159001/pdf/Bookshelf_NBK159001.pdf

446 (Accessed 30 January 2023)

- 447 3. Wessels J, Sherman G, Bamford L, Makua M, Ntloana M, Nuttall J, et al. The updated
448 South African National Guideline for the Prevention of Mother to Child Transmission
449 of Communicable Infections (2019). *South Afr J HIV Med.* 2020;21(1):1–8.
- 450 4. Mirkuzie AH, Sisay MM, Hinderaker SG, Moland KM, Mørkve O. Comparing HIV
451 prevalence estimates from prevention of mother-to-child HIV transmission programme
452 and the antenatal HIV surveillance in Addis Ababa. *BMC Public Health.* 2012;12(1).
- 453 5. Gouws E, Mishra V, Fowler TB. Comparison of adult HIV prevalence from national
454 population-based surveys and antenatal clinic surveillance in countries with
455 generalised epidemics: implications for calibrating surveillance data. *Sex Transm
456 Infect.* 2008;84(Suppl 1):i17-23.
- 457 6. Rehle T, Lazzari S, Dallabetta G, Asamoah-odei E, Rehle T. Second-generation HIV
458 surveillance: better data for decision-making. *Bull World Heal Organ.* 2004;82:121–7.
- 459 7. Dee J, Calleja JMG, Marsh K, Zaidi I, Dee J. HIV Surveillance Among Pregnant
460 Women Attending Antenatal Clinics : Evolution and Current Direction. *JMIR Public
461 Heal Surveill.* 2017;3:1–8.
- 462 8. World Health Organization. Consolidated guidelines on HIV testing services [Internet].
463 2015. Available from: <https://www.who.int/hiv/pub/guidelines/hiv-testing-services/en/>
464 (Accessed 30 January 2023)
- 465 9. Huerga H, Shiferie F, Grebe E, Giuliani R, Farhat J Ben, Van-Cutsem G, et al. A
466 comparison of self-report and antiretroviral detection to inform estimates of
467 antiretroviral therapy coverage, viral load suppression and HIV incidence in Kwazulu-
468 Natal, South Africa. *BMC Infect Dis.* 2017;17(1):1–8.
- 469 10. Osler M, Hilderbrand K, Hennessey C, Arendse J, Goemaere E, Ford N, et al. A
470 three-tier framework for monitoring antiretroviral therapy in high HIV burden settings. *J*

- 471 Int AIDS Soc. 2014;17:18908.
- 472 11. Mofenson LM. Antiretroviral Therapy and Adverse Pregnancy Outcome: The Elephant
473 in the Room? J Infect Dis [Internet]. 2015;jiv390. Available from:
474 <http://jid.oxfordjournals.org/lookup/doi/10.1093/infdis/jiv390>
- 475 12. Jacob N. Western Cape Antenatal Survey Report 2014. Cape Town; 2014.
- 476 13. Woldesenbet S, Kufa T, Lombard C, Manda S, K A, M C, et al. The 2017 National
477 Antenatal Sentinel HIV Survey, South Africa, National Department of Health.
478 [Internet]. 2019. Available from: [https://www.nicd.ac.za/wp-](https://www.nicd.ac.za/wp-content/uploads/2019/07/Antenatal_survey-report_24July19.pdf)
479 [content/uploads/2019/07/Antenatal_survey-report_24July19.pdf](https://www.nicd.ac.za/wp-content/uploads/2019/07/Antenatal_survey-report_24July19.pdf) (Accessed 30
480 January 2023)
- 481 14. Woldesenbet S, Lombard C, Manda S, Kufa T, Ayalew K, Cheyip M, et al. The 2019
482 National Antenatal Sentinel HIV Survey, South Africa [Internet]. 2021. Available from:
483 [https://www.nicd.ac.za/wp-content/uploads/2021/11/Antenatal-survey-2019-](https://www.nicd.ac.za/wp-content/uploads/2021/11/Antenatal-survey-2019-report_FINAL_27April21.pdf)
484 [report_FINAL_27April21.pdf](https://www.nicd.ac.za/wp-content/uploads/2021/11/Antenatal-survey-2019-report_FINAL_27April21.pdf) (Accessed 30 January 2023)
- 485 15. Johnson LF, Dorrington RE. Modelling the impact of HIV in South Africa's provinces:
486 2023 update. Thembisa Version 4.6 [Internet]. 2023. Available from:
487 <https://www.thembisa.org/downloads> (Accessed 30 July 2023)
- 488 16. Johnson LF, Mutemaringa T, Heekes A, Boulle A. Effect of HIV Infection and
489 Antiretroviral Treatment on Pregnancy Rates in the Western Cape Province of South
490 Africa. J Infect Dis. 2020;(July 2019):21–4.
- 491 17. Xia Y, Milwid RM, Godin A, Boily MC, Johnson LF, Marsh K, et al. Accuracy of self-
492 reported HIV-testing history and awareness of HIV-positive status in four sub-Saharan
493 African countries. Aids. 2021;35(3):503–10.
- 494 18. Mavhandu-Ramarumo LG, Tambe LAM, Matume ND, Katerere D, Bessong PO.
495 Undisclosed exposure to antiretrovirals prior to treatment initiation: An exploratory


- 496 analysis. South Afr J HIV Med. 2021;22(1):1–10.
- 497 19. Sithole N, Gunda R, Koole O, Krows M, Schaafsma T, Moshabela M, et al.
498 Undisclosed Antiretroviral Therapy Use at Primary Health Care Clinics in Rural
499 KwaZulu Natal South Africa: A DO-ART Trial Sub-study. AIDS Behav [Internet].
500 2021;25(11):3695–703. Available from: <https://doi.org/10.1007/s10461-021-03319-4>
- 501 20. Kharsany ABM, Cawood C, Lewis L, Yende-Zuma N, Khanyile D, Puren A, et al.
502 Trends in HIV Prevention, Treatment, and Incidence in a Hyperendemic Area of
503 KwaZulu-Natal, South Africa. JAMA Netw Open. 2019;2(11):1–16.
- 504 21. Grobler A, Cawood C, Khanyile D, Puren A, Kharsany ABM. Progress of UNAIDS 90-
505 90-90 targets in a district in KwaZulu-Natal, South Africa, with high HIV burden, in the
506 HIPSS study: a household-based complex multilevel community survey. Lancet HIV.
507 2017;4(11):e505–13.
- 508 22. Jennifer TM-G, Julia R, Livia M, Mark S, Guy H, F.Xavier G-O, et al. ART denial:
509 results of a home-based study to validate self-reported antiretroviral use in rural South
510 Africa. AIDS Behav. 2019;23:2072–8.
- 511 23. Grabowski MK, Reynolds SJ, Kagaayi RH, Clarke W, Chang LC, Nakigozi G et. al.
512 The validity of self-reported antiretroviral use in persons living with HIV: a population-
513 based study. AIDS. 2018;32(3):363–9.
- 514 24. Kim A, Mukui I, Young P, Mirjahangir J, Mwanyumba S, Wamicwe J et. al.
515 Undisclosed HIV infection and ART use in the Kenya AIDS Indicator Survey 2012:
516 relevance to targets for HIV diagnosis and treatment in Kenya. AIDS.
517 2016;30(17):2685–95.
- 518 25. Jacob N, Rice B, Kalk E, Heekes A, Morgan J, Hargreaves J, et al. Utility of digitising
519 point of care HIV test results to accurately measure , and improve performance
520 towards , the UNAIDS 90-90-90 targets. PLoS One [Internet]. 2020;1–13. Available

521 from: <http://dx.doi.org/10.1371/journal.pone.0235471>

522 26. Astawesegn FH, Stulz V, Conroy E, Mannan H. Trends and effects of antiretroviral
523 therapy coverage during pregnancy on mother - to - child transmission of HIV in Sub -
524 Saharan Africa . Evidence from panel data analysis. BMC Infect Dis [Internet].
525 2022;1–13. Available from: <https://doi.org/10.1186/s12879-022-07119-6>


526

527




Figure

Western Cape Antenatal ART Coverage



ART coverage before pregnancy by age-group (2015 - 2020)



ART coverage before or during pregnancy by district (2015 - 2020)

